Kidney Cancer Scotland
Cabo+Tecentriq combo shows promise in advanced ccRCC
Treatment with Cabometyx (cabozantinib) in combination with Tecentriq (atezolizumab) demonstrated promising clinical activity in patients with advanced clear cell renal cell carcinoma... Read More
Day
October 6, 2020
Dive straight into the feedback!Login below and you can start commenting using your own user instantly